Remove Containment Remove Genetic Engineering Remove Immune Response Remove Research
article thumbnail

This week in drug discovery (8-12 April) 

Drug Discovery World

The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so our Friday round-up focuses on drug discovery in oncology. News round-up for 8-12 April by DDW Digital Content Editor Diana Spencer.

Drugs 52
article thumbnail

Pfizer/BioNTech COVID jab works against Brazil variant; lab study

pharmaphorum

The study suggests that serum taken from patients injected with the mRNA shot, also known as BNT162b2, was able to neutralise a genetically engineered version of SARS-CoV-2 with the P.1 The latest research is published in the New England Journal of Medicine. 1 – that is worrying health officials around the world. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AstraZeneca-Oxford COVID-19 Vaccine Shows High Efficacy

XTalks

Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials. The global trials are assessing the safety and efficacy of the vaccine in individuals aged 18 years or over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions.

article thumbnail

Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA

The Pharma Data

President of Research and Development, Novavax. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

article thumbnail

Novavax Announces COVID-19 Vaccine Clinical Development Progress

The Pharma Data

Vaccines Taskforce and National Institute for Health Research played pivotal roles in the rapid recruitment and enrollment of volunteers. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. to determine efficacy and safety of NVX-CoV2373. Novavax was awarded $1.6

article thumbnail

Biopharma Leaders Unite To Stand With Science

The Pharma Data

Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. Sanofi, Empowering Life.

article thumbnail

Biopharma Leaders Unite To Stand With Science

The Pharma Data

continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. Defense Advanced Research Projects Agency.